Latigo Biotherapeutics will apply the IPO proceeds toward a pipeline that includes a next-generation non-opioid pain drug ready for pivotal testing. BlossomHill Therapeutics also debuted on the Nasdaq, raising cash for cancer drugs designed to address mutations not covered by currently available therapies.
The post Latigo Bio’s IPO Lands $346M for Pipeline of Non-Opioid Pain Drugs appeared first on MedCity News.
